Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Myelofibrosis: Patient Monitoring and Triggers to Change Therapy

June 9th 2022

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

Selection and Management of JAK Inhibitor Therapy in MF

June 9th 2022

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Magrolimab Plus Azacitidine Elicits Manageable Anemia in HR-MDS

June 4th 2022

Magrolimab plus azacitidine, at priming and maintenance doses, enables manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, according to results from a prospective phase 1 study (NCT03248479).

Pacritinib Offers Safe and Tolerable Treatment Option for Patients With Myelofibrosis

June 4th 2022

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

Myelofibrosis: Use of Fedratinib and Pacritinib Therapy

June 2nd 2022

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Use of Ruxolitinib in Myelofibrosis

June 2nd 2022

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

Historical Approaches to the Management of MF

May 26th 2022

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Factors in Selecting Therapy for Myelofibrosis

May 26th 2022

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

FDA Places Partial Clinical Hold on Phase 1 Trial Evaluating FHD-286 in Relapsed/Refractory AML and MDS

May 20th 2022

The FDA has placed a partial clinical hold on a phase 1 trial investigating FHD-286 as a treatment for patients with relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome.

Myelofibrosis: Observation and Triggers to Initiate Therapy

May 19th 2022

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Risk Assessment and Staging of Myelofibrosis

May 19th 2022

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Addressing the Challenges in Diagnosing MF

May 12th 2022

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Making a Differential Diagnosis of Myelofibrosis

May 12th 2022

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

Polycythemia Vera: Ruxolitinib Use and Goals of Therapy

May 5th 2022

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Treatment Armamentarium for Polycythemia Vera

May 5th 2022

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

Dr. Verstovsek on the Future of ALK2 Inhibitors in Myelofibrosis

May 4th 2022

Srdan Verstovsek, MD, PhD, discusses the future of ALK2 inhibitors in myelofibrosis.

Dr. Mesa on the Future of JAK Inhibitor Therapy in Myelofibrosis

May 4th 2022

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

Dr. Verstovsek on Addressing Anemia in Patients with Myelofibrosis

May 3rd 2022

Srdan Verstovsek, MD, PhD, discusses addressing anemia in patients with myelofibrosis.

Making a Differential Diagnosis of Polycythemia Vera

April 28th 2022

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

A Brief Overview of Myeloproliferative Neoplasms

April 28th 2022

Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.